

Zydus' Neshor Pharma gets final USFDA nod for Lovaza capsules

17 June 2019 | News

It is used along with diet and exercise to help lower levels of a certain blood fat (triglyceride)



Zydus' Neshor Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA has received the final approval from the USFDA to market Omega-3-Acid Ethyl Esters Capsules USP (US RLD – Lovaza Capsules), 1 gram. Omega-3 acid ethyl esters, a type of fat found in fish oil, is used along with diet and exercise to help lower levels of a certain blood fat (triglyceride). It may also raise good cholesterol (HDL).

The drug will be manufactured at Neshor Pharmaceuticals' manufacturing facility located at St. Louis, MO, USA. The group now has 267 approvals and has so far filed over 360 ANDAs since the commencement of the filing process in FY 2003-04.